Paragon Health Institute Icon White

A Cost That’s Hard to (G)u(LP-1) Down

8MS Glp 1
3AW SMALLER 240409 STHQ DH01 0112
Senior Policy Analyst

Jackson Hammond is a Senior Policy Analyst at Paragon Health Institute. He has been active in the federal and state health policy space since 2017.

Prior to joining Paragon, Jackson was a health care policy analyst for American Action Forum (AAF). While at AAF, his work focused on payer issues including private insurance, Medicare, and Medicare Advantage. Furthermore, Jackson wrote extensively about the 340B Program and contributed to AAF’s research on a variety of drug pricing issues.

On October 8, the Congressional Budget Office (CBO) released a report on the potential federal cost if Medicare decides to cover anti-obesity medications (AOMs) for weight loss, including the much-discussed class of glucagon-like peptide 1’s (GLP-1s). CBO’s results were not encouraging: The agency projects that net federal spending would increase around $35.5 billion between 2026 and 2034 and would continue to increase through 2044. The reason is a complex mix of the cost of the drug itself, GLP-1s’ impact on health outcomes, and the fact that most preventive health measures do not reduce federal health spending. Given these complexities, CBO acknowledges a lot of uncertainty involved in these calculations. In the background of all this is a brewing fight over paying for GLP-1s, with Medicare just the tip of the spear. Below, I’ll examine the report, its implications, and what broader coverage of GLP-1s means for drug policy in the United States.

CBO’s Estimates

CBO looked at a policy that would cover AOMs for any Medicare enrollee that qualifies for them – namely, those who are obese (34 percent of Medicare enrollees) and those who are overweight with a weight-related chronic condition. Between 2026 and 2034, CBO expects federal spending to increase roughly $35.5 billion. That includes $38.8 billion in direct costs of covering AOMs as well as $3.4 billion in savings from improved health. CBO estimates that it would cost $1.5 billion to the federal government in the first year alone, rising to $6.1 billion in 2034 (see figure 1). Costs per user would decline over time, from $5,600 per person in 2026 to $4,300 per person in 2034, but are likely to be offset by increased uptake.

Figure 1: Costs of Covering Anti-Obesity Medications in Medicare Outweigh Savings in First 10 Years

 
CBO expects the costs (which would be in Part D) to continue to outweigh the savings (which would mostly be in Part A and some in Part B) into a second decade through 2044, though the gap between the two will decrease. CBO expects the above-noted cost per user to go down as more competitors enter the market (though CBO notes that brand prices may not drop if the drugs get better as manufacturers compete on quality as well as price), more generic alternatives appear, more people use AOMs and for longer periods of time, as well as if beneficiaries who were already on AOMs prior to joining Medicare continued their treatment.

No Certainty

There’s a lot of uncertainty with these estimates, which CBO admits. We don’t know how the prices of novel GLP-1s will change, we don’t know what new GLP-1s will be introduced, we don’t know how many generics there will be, we don’t know how many people will ultimately use them, we don’t know how long people will stay on them, we don’t know what Medicare drug price “negotiations” will do to the price, and we don’t even know if reducing obesity impacts long-term health spending.

That last part is crucial; CBO points out that the studies we have on this topic “rely on correlations between [body mass index (BMI)] and health conditions and between health conditions and health care spending, which may or may not be driven by a causal relationship.” As CBO notes, there is a correlation between higher BMIs and higher health care spending; as BMI increases above 25, average annual health care spending among Medicare beneficiaries increases. But we don’t know if losing that weight, after perhaps decades of being overweight or obese, causes the chronic conditions that are associated with obesity to fully go away or lessen. Type II diabetes, for example, becomes more manageable with a healthier lifestyle and weight loss, but is not curable. GLP-1s are expensive, between $900-$1,300 a month before rebates in the private market, and actual health savings may never reach that high on average. CBO is assuming a cheaper per-user price from Part D rebates in the first year and then Medicare “negotiations” starting in 2027.

Two recent microsimulations discussed in the CBO report, one by the Institute for Clinical and Economic Review (ICER) and the other by the University of Southern California’s (USC’s) Schaeffer Center, sought to answer the savings question. ICER found that the net cost of GLP-1s was four times that of the savings. USC’s study reported $175 billion in “cost offsets” (not savings, as the USC study did not estimate what it would cost Medicare to cover GLP-1s) for Medicare over 10 years through GLP-1 coverage. The USC study came with some major caveats however: It assumed 100 percent uptake, perfect compliance, and continual use by beneficiaries for the rest of their lives – “conditions that are not achievable in practice,” to quote CBO. Given the known side effects of GLP-1s such as intestinal discomfort and muscle loss, most people have trouble staying on them for more than a year and the weight loss is often reversed once they stop.

We also don’t know much about the relative effects of weight loss on mortality. CBO notes that some analyses of weight loss via GLP-1s found they reduced all-cause mortality in certain patients, while other methods had mixed results – notably bariatric surgery, which did not clearly lower future health spending and was heavily dependent on individual adherence to post-surgery lifestyle changes. This is important for federal budgets because longer life spans impact government spending in a morbid but important way: The longer people live, the longer they utilize Social Security and Medicare – the largest drivers of our federal debt.

What It’s Really About

CBO is exploring GLP-1s because these drugs have made AOMs a much more promising weight loss solution than in years past. So much so, in fact, that Congress is considering legislation that would partly lift the two-decade prohibition on Medicare coverage of AOMs.

Ultimately, however, advocates for GLP-1s (both patients and pharmaceutical companies) want to see full Medicare coverage. This is partially because advocates want the latest medications available to the Medicare population, but also because they believe private insurers might follow Medicare’s lead. Most insurers currently cover GLP-1s, but only for treating diabetes and certain cardiac conditions. However, more and more employers are offering GLP-1 coverage for weight loss: 34 percent in 2024, up from 26 percent the year prior. Advocates have also correctly noted that there isn’t a single other medicine where Medicare considers the cost of a drug relative to its potential savings in determining coverage – but maybe Medicare should start doing so. There are very few medicines covered by Medicare that cost anywhere close to $35 billion over 10 years.

The Coming Access Fight

The debate over whether to cover GLP-1s in Medicare is really a part of the much larger debate in drug policy about value: Are the drugs we take worth the prices we pay for them? News articles abound about the fears around high prices for GLP-1s, and Senators are claiming the prices are “unjustifiably high” because of how many patients could benefit from them if they were cheaper. That logic is self-defeating: If GLP-1s really are worth that much to Americans’ health, then they are worth paying the market price – and worth enough that other suppliers will want to introduce competitors to meet Americans’ needs.

As relatively new drugs with huge potential to help treat our obesity crisis and an ever-growing list of indications, GLP-1s may be truly valuable even at the high price – for a given individual. The problem is when we start looking to public insurance programs to cover them. Medicare spent over $1 trillion last year and is the single biggest fiscal issue for the nation – policymakers shouldn’t add major new expenditures without taking a hard look at how much benefit they provide not just in terms of claimed savings, but in total health outcomes relative to other options. So far, the full potential of GLP-1s is unknown. Studies on long-term use, adherence, and related potential side-effects do not exist. Given all these unknowns, it may be best for Congress to pump the brakes on expanding GLP-1s in Medicare before we have a better understanding of their full value – and a way to pay for it.

Related Content

Subscribe

Sign up now for your health policy updates.

This field is for validation purposes and should be left unchanged.
Name(Required)